• 1. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 2. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 3. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 4. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 5. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxepanes Oxepanes
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxepanes

Chemical Profile of (1R,4S,6S)-1-Methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptane (CAS No. 42477-94-1)

CAS No. 42477-94-1 refers to a specific chemical compound known as (1R,4S,6S)-1-Methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptane, a complex organic molecule with a unique bicyclic structure. This compound has garnered attention in the field of pharmaceutical chemistry due to its structural complexity and potential biological activity. The bicyclo[4.1.0]heptane core, characterized by its fused ring system, presents a challenging yet intriguing scaffold for medicinal chemists seeking to develop novel therapeutic agents.

The stereochemistry of (1R,4S,6S)-1-Methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptane is meticulously defined by the (1R,4S,6S) configuration, which plays a crucial role in determining its interactions with biological targets. The presence of a methyl group at the 1-position and an allyl group at the 4-position further enhances its structural diversity, making it a promising candidate for further exploration in drug discovery.

In recent years, there has been significant interest in developing new methodologies for the synthesis of complex cyclic compounds like (1R,4S,6S)-1-Methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptane. Advances in organic synthesis have enabled more efficient and scalable routes to these molecules, which are often challenging to produce due to their strained ring systems and multiple stereocenters. Techniques such as transition-metal-catalyzed reactions and asymmetric synthesis have been particularly valuable in constructing these intricate structures with high enantioselectivity.

The potential biological activity of (1R,4S,6S)-1-Methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptane has been explored in several preclinical studies. Its unique structural features suggest that it may interact with various biological targets, including enzymes and receptors involved in metabolic pathways or signal transduction processes. While comprehensive pharmacological data is still limited, preliminary studies indicate that this compound exhibits promising properties that warrant further investigation.

One of the key areas of research involving (1R,4S,6S)-1-Methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptane is its potential role as a scaffold for drug design. The bicyclic framework offers a rigid structure that can be modified to optimize binding affinity and selectivity towards specific biological targets. By leveraging computational modeling and structure-based drug design approaches, researchers can predict how modifications to the core structure might influence its biological activity.

The synthesis of derivatives of (1R,4S,6S)-1-Methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptane has also been a focus of recent studies. By introducing various functional groups or altering the stereochemistry at key positions, scientists aim to enhance the pharmacological properties of this compound. Such modifications can lead to improved solubility, bioavailability, or target specificity, making them crucial steps in the development of novel therapeutics.

Another exciting aspect of studying (1R,4S,6S)-1-Methyl-4-(prop-1-en-2-y l)-7 oxabicyclo[41 0]heptane is its potential application in combinatorial chemistry and high-throughput screening (HTS) platforms. The ability to generate libraries of related compounds allows researchers to rapidly screen for bioactive molecules without extensive manual synthesis efforts. This approach has accelerated the discovery process in drug development and has led to the identification of several lead compounds with therapeutic potential.

The future direction of research on (CAS No 42 47794 91) will likely involve exploring its pharmacological profile in greater detail through both in vitro and in vivo studies. Understanding how this compound interacts with biological systems will provide valuable insights into its mechanism of action and potential therapeutic applications.

Additionally as synthetic methodologies continue to evolve researchers will be able to access more complex derivatives of this compound with greater ease This will open up new avenues for drug discovery and allow for more sophisticated modifications to be made which could lead to breakthroughs in treating various diseases

• 1139-30-6(Caryophyllene oxide)
• 1195-92-2(1-methyl-4-(prop-1-en-2-yl)-7-oxabicyclo4.1.0heptane)
• 6909-30-4((+)-trans-Limonene Oxide)
• 4680-24-4((+)-cis-limonene 1,2-epoxide)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)